No more double standards
False, misleading or fraudulent claims have long brought the wrath of juries, judges and government agencies down on perpetrators. So have substandard manufacturing practices. GlaxoSmith Klein has agreed to plead guilty and pay a $750-million fine for manufacturing deficiencies at a former pharmaceuticals plant. Even though there was no indication of patient harm, said the US attorney, the fine was needed “to pressure companies to follow the rules.” Johnson & Johnson was recently slapped with a $258-million jury verdict for allegedly misleading claims about the safety and superiority of an antipsychotic drug. J&J’s actions “defrauded the Louisiana Medicaid system,” prosecutors argued. [...]